The IMpower150 trial reported better OS and PFS with atezolizumab, bevacizumab, carboplatin and paclitaxel, compared to bevacizumab, carboplatin and paclitaxel in patients with non-squamous NSCLC, including those with EGFR mutations, and those who had received prior TKIs [226]. Here, EGFR is linked to non-small cell lung carcinoma.